Shares of Insulet Corp. PODD slid 1.90% to $282.80 Friday, on what proved to be an all-around dismal trading session for the ...

Insulin delivery company Insulet Corporation (NASDAQ:PODD) reported Q4 CY2024 results , with sales up 17.2% year on year to ...

Insulet (NASDAQ:PODD – Get Free Report) had its price target boosted by equities researchers at Citigroup from $310.00 to $355.00 in a note issued to investors on Friday,Benzinga reports. The ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Q4 2024 Management View CEO Jim Hollingshead highlighted the company’s achievement of $2.1 billion in revenue for 2024, marking a doubling of revenue in just three years. He emphasized the strong ...

Investors eyeing a purchase of Insulet Corp (Symbol: PODD) shares, but tentative about paying the going market price of $286.60/share, might benefit from considering selling puts among the ...

Good afternoon ladies and gentlemen and welcome to the Insulet Corporation Fourth Quarter and Full Year 2024 Earnings Call. At this time all participants are in a listen-only mode. Later we will ...

How far off is Insulet Corporation (NASDAQ:PODD) from its intrinsic value? Using the most recent financial data, we'll take a look at whether the stock is fairly priced by taking the expected ...

ACTON, Mass. (AP) — ACTON, Mass. (AP) — Insulet Corp. (PODD) on Thursday reported fourth-quarter profit of $100.7 million. On a per-share basis, the Acton, Massachusetts-based company said it had net ...

Insulet Corporation ended 2024 with strong momentum, driven by record revenues, robust gross margin expansion, and successful market penetration of Omnipod 5 in both type 1 and type 2 diabetes.